A Letter from Novartis 諾華公司的一封信

John Tsai

Global Drug Development

全球藥品研發(fā)部

Dear Colleagues,

各位同事,

I hope by now you have had the opportunity to go through the quarterly results for Q3 2018, announced last week.

上周，我們公布了2018年第三季度業(yè)績(jì)，各位現在應該都已了解了相關(guān)內容。

It is fair to say that they were impressive.

可以說(shuō)，這樣的業(yè)績(jì)十分喜人。

I’m sure you feel as proud as I do of the contribution that the GDD organization has made to this success.

我相信大家和我一樣，為GDD部門(mén)在其中所做的貢獻而感到自豪。

For this quarter, we received key approvals and regulatory opinions for nine transformative treatments, including Aimovig for migraine prevention, Kymriah both for adults with DLBCL and children with ALL, Tafinlar/Mekinist for people with BRAF V600-mutant melanoma, Kisqali as a first-line treatment for HR+/HER2- metastatic breast cancer and Gilenya to treat children and adolescents with MS.

本季度，我們收到了九項變革性療法的關(guān)鍵性批準和監管意見(jiàn)，其中包括用于預防偏頭痛的藥物Aimovig、用于治療細胞淋巴瘤（DLBCL）成年患者和急性淋巴細胞白血病（ALL）兒童患者的藥物Kymriah、用于治療BRAF V600突變黑色素瘤患者的藥物Tafinlar/Mekinist、用于一線(xiàn)治療HR+/HER2轉移性乳腺癌的藥物Kisqali，以及用于治療兒童及青少年多發(fā)性硬化癥（MS）的藥物Gilenya。

We achieved key regulatory submissions, including for siponimod in a difficult-to-treat stage of MS, and announced many more major trial results.

我們完成了主要的監管性提交，包括用于多發(fā)性硬化癥難治性階段的藥物siponimod，而且公布了許多重要的試驗結果。

We also announced our planned acquisition of Endocyte to accelerate development of novel radiopharmaceutical technology for treating cancer.

我們還宣布了收購Endocyte公司的計劃，以加速開(kāi)發(fā)用于治療癌癥的新型放射性藥物技術(shù)。

All this and more, in Q3 alone.

所有這些都僅僅是第三季度所取得的成績(jì)，當然，第三季度的成果還遠不止這些。

And what is key is not just the quantity, but the quality of the milestones.

但這些成績(jì)的關(guān)鍵并不在于數量，而在于其具有里程碑意義的質(zhì)量。

In these successes – and even in our disappointments, such as the FDA’s decision not to support our application for canakinumab in CV risk reduction – we see tangible evidence of our bold approach to scientific innovation.

無(wú)論是我們獲得的成功，還是遭遇的挫折，例如，FDA駁回了我們有關(guān)利用降低心血管疾病風(fēng)險的申請，都有力地證明了我們在大膽進(jìn)行科學(xué)創(chuàng )新。

To continue and build on this, we must drive medical innovation while simultaneously embracing external trends.

為了延續這一良好的發(fā)展勢頭，我們必須積極推動(dòng)醫療創(chuàng )新，同時(shí)順應行業(yè)發(fā)展趨勢。

Since I joined GDD, I have consistently talked about the areas we must focus on to achieve this, with a clear emphasis on our portfolio, data and digital projects, operational excellence, and culture.

自加入GDD以來(lái)，我一直在談?wù)撐覀優(yōu)閷?shí)現這一目標而必須重點(diǎn)關(guān)注的領(lǐng)域，并明確要著(zhù)重于產(chǎn)品組合、數據和數字化項目、卓越運營(yíng)以及企業(yè)文化等方面。

In recent weeks, I have been working with members of the DCN to refine our GDD strategy to ensure it reflects our latest thinking, and I am pleased to share that with you now.

最近幾周，我與DCN成員一道，改進(jìn)完善了GDD戰略，確保它能體現我們最新的想法和觀(guān)點(diǎn)。我很高興現在能與大家分享相關(guān)內容。

I want us all to be clear on our approach and the language we will use going forward when talking about our priorities.

我希望大家都清楚我們所遵循的方針，明白我們在未來(lái)討論重點(diǎn)事項時(shí)將使用的表述。

I appreciate there is a lot of terminology used around our strategy and I want to simplify to ensure we are consistent in our understanding and our messaging across the organization.

之前的戰略中使用了很多術(shù)語(yǔ)，這一點(diǎn)我很欣賞，但我想更簡(jiǎn)單一些，確保在整個(gè)部門(mén)中，理解和信息傳遞做到一致無(wú)誤。

As you know, our purpose at Novartis is to Reimagine Medicine, which our company has done consistently for the last 100 years, contributing a huge amount to society during that time.

如你們所知，諾華的宗旨是重新定義醫學(xué)，公司在過(guò)去百年里也一直在為此而努力，為社會(huì )做出了巨大的貢獻。

We will only continue to be successful if we develop and implement a clear GDD strategy, as follows:

只有制定并實(shí)施明確的GDD戰略，我們才能繼續取得成功，其中包括：

·    Deliver breakthrough innovation:

     實(shí)現突破性創(chuàng )新：

We will continue to build a pipeline of innovative medicines that address high unmet needs and improve and extend people’s lives across the world.

我們將繼續構建創(chuàng )新型藥物的研發(fā)體系，解決全球范圍內未滿(mǎn)足的醫療需求，延長(cháng)人們的壽命，改善生活質(zhì)量。

We will achieve this by prioritizing the medicines that will have the most impact for patients, and by establishing the innovative platform technologies we need to deliver them.

我們將通過(guò)優(yōu)先開(kāi)發(fā)療效最為顯著(zhù)的藥物，并建立相應的創(chuàng )新型平臺技術(shù)來(lái)實(shí)現這一目標。

·   Unleash the power of data and digital:

    釋放數據和數字化的力量：

Data and digital will help us to identify these innovative medicines and accelerate their development.

數據和數字化技術(shù)將有助于發(fā)掘創(chuàng )新型藥物，同時(shí)加速藥物開(kāi)發(fā)。

We will use all available data to generate insights about diseases, patients and treatments.

我們將充分利用各類(lèi)可用數據，對疾病、患者和療法進(jìn)行深入研究。

We will use technologies that improve the patient experience, and we will embed tools to improve our end-to-end clinical trial processes.

我們將運用能改善患者體驗的技術(shù)，同時(shí)借助各種工具改進(jìn)端到端的臨床試驗流程。

·   Embrace operational excellence:

    邁向卓越運營(yíng)：

Implementing a step-change in how we operate will bring these innovative and impactful medicines to patients as quickly as possible.

落實(shí)運營(yíng)方式的重大變革，讓有效的創(chuàng )新型藥物盡早為患者帶去福音。

We will implement better resource prioritization, simplified governance and strengthened NIBR / GDD collaboration to reduce our development cycle times.

我們將采用更加合理的資源優(yōu)先次序，簡(jiǎn)化管理并加強NIBR與GDD的合作，縮短藥物研發(fā)周期。

·   All underpinned by our inspired, curious and unbossed culture:

    以鼓舞人心、好奇求知、去領(lǐng)導化的文化為后盾：

We want everyone to feel inspired, empowered to be their best self, and to live our values and behaviors.

我們不斷鼓舞每位員工，讓他們奮發(fā)向上，充分發(fā)揮自身的價(jià)值，積極踐行我們的價(jià)值觀(guān)及行為方式。

We will support leaders to become more effective in role modelling and coaching, we will enable good decision-making, and we will further embed our culture throughout GDD.

我們會(huì )為領(lǐng)導者提供必要的支持，讓他們起到更好的帶頭模范作用，讓指導工作更加有效的開(kāi)展；我們會(huì )讓決策更加明智；我們還會(huì )在GDD整個(gè)部門(mén)內深入推廣這種文化。

I hope you agree this is not a radical change in direction but rather an evolution.

我希望大家清楚，這并不是方向上的巨變，而是一種發(fā)展進(jìn)步。

More detail can be found in these slides.

如需了解詳細內容，可查看這些幻燈片。

I will also be providing further information on each element of this strategy over the coming weeks, starting with data and digital.

在接下來(lái)的幾周里，我將從數據和數字化著(zhù)手，詳細介紹這一戰略中的各個(gè)要素。

In the meantime, I want to thank you for the ongoing high quality of your work, which continues to impress me enormously.

同時(shí)，我要感謝大家一直以來(lái)對工作的傾情投入，你們的出色表現給我留下了深刻印象。

I believe that if we realize our strategy, we will go on to achieve even greater things, together.

我堅信，只要切實(shí)踐行戰略，我們就能共同再創(chuàng )佳績(jì)。

Kind regards,

親切問(wèn)候,

John